Skip to main content
OpenTrials
Completed

NCT Number: NCT01257009

Atorvastatin and Sympathetic Activity in Chronic Kidney Disease

Hypertensive chronic kidney disease (CKD) patients often have sympathetic hyperactivity which appears to contribute to the pathogenesis of hypertension and cardiovascular organ damage. Experimental studies and some clinical studies have shown that statin therapy can reduce central sympathetic activity. Blockade of the renin-angiotensin system (RAS), which is standard treatment for CKD, is known to lower sympathetic activity.

The investigators hypothesize that adding a statin for 6 weeks to RAS blockade would further lower sympathetic activity in hypertensive stage 2-4 CKD patients.

Methods: In ten stable CKD patients who are on chronic treatment with renin-angiotenis blockers, blood pressure and sympathetic activity (quantified by assessment of muscle sympathetic nerve activity, MSNA) will be assessed at baseline and 6 weeks after atorvastatin 20mg/day added.

Ten other CKD patients will serve as time control and will be studied twice with an interval of 6 weeks without any change in medication, to quantify within subject reproducibility.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Stable Chronic Kidney Disease Cardiovascular Diseases Chronic Disease Disease Attributes Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Hypertension Kidney Diseases Male Urogenital Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Renal Insufficiency Renal Insufficiency, Chronic Urogenital Diseases Urologic Diseases Vascular Diseases

Age range

18 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

University Medical Center utrecht

Utrecht, 3584CX, Netherlands

About this study

see above

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • stable chronic kidney disease
  • Hypertension

Exclusion criteria

  • renal replacement therapy
  • pregnancy
  • diabetes mellitus

Treatment and study plan

atorvastatin

Drug

6 weeks treatment with atorvastatin and studying the effect of atorvastatin on sympathetic activity

Other names: Lipitor

Primary outcomes

  1. Sympathetic activity

    Time frame: 4-6 weeks treatment

Sponsors and collaborators

Lead sponsor

UMC Utrecht

Other

Registry information

Official study title

Atorvastatin Reduces Sympathetic Activity in Patients With Chronic Kidney Disease

Important dates

Study start
2009
Primary completion
2010
Study completion
2010
First posted
Dec 9, 2010
Registry last updated
Dec 9, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.